You are here: Industry Insights > Cheplapharm

News List

AstraZeneca divests Atacand commercial rights to Cheplapharm pharmaceutical-technology.
January 06, 2021
AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus in over 70 countries to German pharmaceutical firm Cheplapharm Arzneimittel.
AstraZeneca to Sell Atacand, Atacand Plus Commercial Rights to Cheplapharm americanpharmaceuticalreview
November 06, 2020
AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in around 70 countries globally to Cheplapharm Arzneimittel GmbH.
Takeda sells select non-core assets in Europe to Cheplapharm for about $562 mn expresspharma
September 17, 2020
Portfolio includes prescription products in Takeda’s cardiovascular/metabolic and anti-inflammatory therapeutic areas along with calcium.
LEO Pharma divests four medicines to Cheplapharm for $357m pharmaceutical-technology
September 01, 2020
Danish medical dermatology company LEO Pharma has divested a portfolio of four non-core medicines to German pharmaceutical firm Cheplapharm for €300m ($357m).
AstraZeneca closes deal with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia pharmaceutical-business-review
December 20, 2019
AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR ...
Agreement with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia completed worldpharmanews
December 17, 2019
AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) ...
AstraZeneca sells Atacand rights to Cheplapharm pharmatimes
July 25, 2018
AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries.